Market Research Logo

Global Musculoskeletal Disorders Therapeutics Market 2016-2020

Global Musculoskeletal Disorders Therapeutics Market 2016-2020

About Musculoskeletal Disorders

Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide range of causes, but usually occur depending on the age, lifestyle, and occupation of an individual. Symptoms usually range from recurrent pain, stiffness, and swellings. X-rays and other medical imaging procedures may diagnose the condition. The treatment mainly depends on the severity of the condition. Apart from the drugs, physical therapy, and occupational therapy are also used to manage the condition.

Technavio’s analysts forecast the global musculoskeletal disorder therapeutics market to grow at a CAGR of 4.46% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global musculoskeletal disorder therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic arthritis, and fibromyalgia.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Musculoskeletal Disorder Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Johnson & Johnson
  • Amgen
  • Pfizer
  • F. Hoffmann-La Roche
  • Eli Lilly
Other prominent vendors
  • 3SBio
  • AB Sciences
  • AbGenomics International
  • Ablynx
  • Adheron
  • Akron Molecules AG
  • Alder BioPharmaceuticals
  • Amgen Astellas BioPharma K.K. in Japan
  • Ampio Pharmaceuticals
  • Antares Medical Services
  • Astellas
  • AstraZeneca
  • Baxter
  • Biocad
  • Bioiberica
  • Boehringer Ingelheim
  • Bone Therapeutics
  • Can-Fite BioPharma
  • Celgene
  • Celltrion
  • Cellular Biomedicine
  • Cerapedics
  • ChemoCentryx
  • Chugai Pharmaceutical
  • Coherus Biosciences
  • Daiichi Sankyo
  • Dong-A ST
  • Edding Pharm
  • Eisai
  • Epirus
  • Eupraxia Pharmaceuticals
  • Flexion Therapeutics
  • Galapagos NV
  • Gedeon Richter
  • Gilead Sciences
  • GlaxoSmithKline
  • Histogenics
  • IBSA Institut Biochimique
  • iCeutica
  • Iltoo Pharma
  • Incyte
  • Innovative Med Concepts
  • Iroko Pharmaceuticals
  • ISTO Technologies
  • KaloBios Pharmaceuticals
  • KAN Research Institute
  • Kang Stem Biotech
  • Kitov Pharmaceuticals
  • Lexicon Pharmaceuticals
  • LG Life Sciences
  • MEDIPOST
  • Medivir
  • Merck
  • Mereo
  • Mesoblast
  • MOCHIDA PHARMACEUTICAL
  • MorphoSys
  • Morphotek
  • Mycenax
  • Neomed Institute
  • Novartis
  • Omeros
  • OrthoTrophix
  • Osteologix
  • OxyPharma
  • PFEnex
  • Philogen
  • PhytoHealth
  • Plexxikon
  • PLx Pharma
  • Protalex
  • Proximagen
  • Radius Health
  • Regeneron Pharmaceuticals
  • Samsung Bioepis
  • Samumed
  • Sandoz
  • Sanofi
  • SantoSolve AS
  • Steminent Biotherapeutics
  • Stempeutics Research
  • Taiwan Liposome Company
  • Takeda
  • Tarsa Therapeutics
  • Techfields Pharma
  • Tetec AG
  • TheraMAB
  • TiGenix
  • TissueGene
  • Tonix Pharmaceuticals
  • Translational Biosciences
  • UCB
  • Vericel
  • Vertex Pharmaceuticals
  • Vitaeris
  • Winston Laboratories
  • Zosano Pharma
Market driver
  • Tentative approval of advanced drugs
  • For a full, detailed list, view our report
Market challenge
  • Growing preference toward surgeries
  • For a full, detailed list, view our report
Market trend
  • Ongoing active clinical trials for biosimilars
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Musculoskeletal Disorder Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the global musculoskeletal disorder therapeutics market: AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche, and Eli Lilly.

Other Prominent Vendors in the market are: 3SBio, AB Sciences, AbGenomics International, Ablynx, Adheron, Akron Molecules AG, Alder BioPharmaceuticals, Amgen Astellas BioPharma K.K. in Japan, Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica, Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene, Celltrion, Cellular Biomedicine, Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST, Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma, Incyte, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals, KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys, Morphotek, Mycenax, Neomed Institute, Novartis, Omeros, OrthoTrophix, Osteologix, OxyPharma, PFEnex, Philogen, PhytoHealth, Plexxikon, PLx Pharma, Protalex, Proximagen, Radius Health, Regeneron Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent Biotherapeutics, Stempeutics Research, Taiwan Liposome Company, Takeda, Tarsa Therapeutics, Techfields Pharma, Tetec AG, TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, and Zosano Pharma.

Commenting on the report, an analyst from Technavio’s team said: “Growing focus toward abuse-resistant novel drugs will be a key trend for market growth. Drug abuse is normally seen in individuals who are on opioid therapy to treat chronic pain in musculoskeletal disorders. Pain associated with musculoskeletal disorders are among the top causes of disability worldwide. There have been many instances where pain therapeutics such as Vicodin, OxyContin, and Dilaudid have been prescribed widely. This was because of the influence of pharmaceutical companies promoting their drugs for enhanced sales. Pharma companies are under constant pressure from regulatory bodies to develop novel abuse-resistant drugs. There is an increased need among pharma and biotech companies to develop abuse-resistant medicinal products to treat musculoskeletal disorders with minimal or no abuse. Off-late, researchers, and vendors are focusing on developing abuse-resistant novel drugs.”

According to the report, preference for combination therapies will be a key driver for market growth. Combination therapies are preferred over monotherapies due to their improved efficacy. For instance, to treat rheumatoid arthritis, more than one of the standard DMARDs is used with or without short-term steroids. Methotrexate is given in combination with sulfasalazine or with other DMARDs. Administering a combination of anabolic and antiresorptive agents can enhance bone density and bone strength better than either agent given as a monotherapy. Clinical trials have been performed to evaluate combinations of PTH1-34 or PTH1-84 with antiresorptives, including raloxifene, alendronate, risedronate, ibandronate, zoledronic acid, and denosumab. Also, the effects of combination therapies are site dependent. The most consistent result of combining antiresorptive drugs with PTH or teriparatide is a greater hip BMD outcome compared with these drugs given as monotherapies. For instance, Pfizer's Duavee combines conjugated estrogens with bazedoxifene to treat postmenopausal osteoporosis with few side effects.

Further, the report states that multiple patent expiries will be a challenge for the market. Patent expiries result in the loss of exclusivities of the specific drug, leading to a rapid decline in its sales. Also, the entry of generic versions of the drugs will lead to further loss of revenue for drug manufacturers, hindering market growth. Branded biologics, such as Humira, Enbrel, and Remicade, are set to lose their patent exclusivities during the forecast period. For instance, Roche's Rituxan lost its patent protection in 2013 in Europe, and is set to lose the same in December 2015 in the US. These biological products, with global sales of over $20 billion, will lose their patent protection by 2020, intensifying the competition to develop their biosimilars.

Companies Mentioned

AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche, Eli Lilly, 3SBio, AB Sciences, AbGenomics International, Ablynx, Adheron, Akron Molecules AG, Alder BioPharmaceuticals, Amgen Astellas BioPharma K.K. in Japan, Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica, Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene, Celltrion, Cellular Biomedicine, Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST, Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma, Incyte, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals, KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys, Morphotek, Mycenax, Neomed Institute, Novartis, Omeros, OrthoTrophix, Osteologix, OxyPharma, PFEnex, Philogen, PhytoHealth, Plexxikon, PLx Pharma, Protalex, Proximagen, Radius Health, Regeneron Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent Biotherapeutics, Stempeutics Research, Taiwan Liposome Company, Takeda, Tarsa Therapeutics, Techfields Pharma, Tetec AG, TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, Zosano Pharma.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key customer segments for musculoskeletal disorder therapeutics
      • Table Impact of biologics on various sectors
  • Pipeline portfolio
    • Table Pipeline portfolio: Global rheumatoid arthritis drugs market
    • Table Pipeline portfolio: Global osteoarthritis drugs market
    • Table Pipeline portfolio: Global osteoporosis drugs market
    • Table Pipeline portfolio: Global psoriatic arthritis drugs market
    • Table Pipeline portfolio: Global fibromyalgia drugs market
    • Table Pipeline portfolio: Global ankylosing spondylitis drugs market
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global musculoskeletal disorder therapeutics market 2015-2020 ($ billions)
      • Table Patient assistance programs offered by companies
      • Table CAM therapies for rheumatoid arthritis
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by disease type
    • Table Segmentation of global musculoskeletal disorder therapeutics market
    • Table Segmentation of global musculoskeletal disorder therapeutics market by revenue 2015
    • Rheumatoid arthritis
    • Osteoarthritis
    • Osteoporosis
    • Psoriatic arthritis
    • Ankylosing spondylitis
    • Fibromyalgia
  • Global rheumatoid arthritis drugs market
    • Market overview
      • Table Opportunities in rheumatoid arthritis drugs industry
      • Table Global rheumatoid arthritis drugs market 2015-2020 ($ billions)
  • Global osteoarthritis drugs market
    • Market overview
      • Table Unmet medical needs with current osteoarthritis treatments
      • Table Global osteoarthritis drugs market 2015-2020 ($ billions)
  • Global osteoporosis drugs market
    • Market overview
      • Table Global osteoporosis drugs market 2015-2020 ($ billions)
  • Global ankylosing spondylitis drugs market
    • Market overview
      • Table Global ankylosing spondylitis drugs market 2015-2020 ($ billions)
  • Global psoriatic arthritis drugs market
    • Market overview
      • Table Global psoriatic arthritis drugs market 2015-2020 ($ billions)
  • Global fibromyalgia drugs market
    • Market overview
      • Table Global fibromyalgia drugs market 2015-2020 ($ billions)
  • Market segmentation by type of molecule
    • Table Segmentation of global musculoskeletal disorder therapeutics market by type of molecules 2015
    • Biologics
    • Small molecules
  • Market segmentation by route of administration
    • Table Segmentation of global musculoskeletal disorder therapeutics market by ROA 2015
    • Parenteral
    • Topical
    • Oral
  • Geographical segmentation
    • Global musculoskeletal disorder therapeutics market by geography 2015-2020
      • Table Global musculoskeletal disorder therapeutics market by geography 2015-2020
      • Table Global musculoskeletal disorder therapeutics market segmentation by geography 2015-2020 ($ billions)
      • Table Global share of musculoskeletal disorders therapeutics market by geography 2015
      • Table Global musculoskeletal disorder therapeutics market: Country analysis based on revenue and growth rate
    • Musculoskeletal disorders therapeutics market in Americas
      • Table Musculoskeletal disorders therapeutics market in Americas 2015-2020 ($ billions)
    • Musculoskeletal disorders therapeutics market in EMEA
      • Table Musculoskeletal disorders therapeutics market in EMEA 2015-2020 ($ billions)
    • Musculoskeletal disorders therapeutics market in APAC
      • Table Musculoskeletal disorders therapeutics market in APAC 2015-2020 ($ billions)
  • Market drivers
    • High growth potential of mAbs
      • Table Few of the late-stage mAbs under development for various musculoskeletal disorders
    • Unmet needs of therapeutics
    • Tentative approval of advanced drugs
    • Technological advancements in medical imaging
    • Combination therapies
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Non-adherence to treatment regimen
    • Growing preference toward surgeries
    • Multiple patent expiries
      • Table Approval and patent expiries of top selling biologics
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Focus on regenerative medicines
    • Ongoing active clinical trials for biosimilars
    • Growing focus toward abuse-resistant novel drugs
  • Vendor landscape
    • Competitive scenario
      • Table Key vendors ranking 2015
      • Table Geographical presence of key vendors
      • Table Competitive scenario of global musculoskeletal disorder therapeutics market vendors 2015-2020
  • Key vendor analysis
    • AbbVie
      • Table AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
      • Table AbbVie: Geographical segmentation of Humira 2015
      • Table AbbVie: Metrics analysis
    • Johnson & Johnson
      • Table Key products in musculoskeletal disorders market with 2015 revenues
      • Table Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Stelara 2013-2015 ($ billions)
      • Table Johnson & Johnson: Metrics analysis
    • Amgen
      • Table Amgen: YoY revenue and growth rate of Enbrel (US and Canada) 2013-2015 ($ billions)
      • Table Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ billions)
      • Table Amgen: Geographical segmentation of Prolia 2015
      • Table Amgen: Metrics analysis
    • Pfizer
      • Table Key products in musculoskeletal disorders market with 2015 revenues
      • Table Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
      • Table Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
      • Table Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions)
      • Table Pfizer: YoY revenue and growth rate of Xeljanz 2013-2015 ($ millions)
      • Table Pfizer: Metrics analysis
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of MabThera/Rituxan by revenue 2015
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Actemra/RoActemra by revenue 2015
      • Table F. Hoffmann-La Roche: Metrics analysis
    • Eli Lilly
      • Table Eli Lilly: YoY revenue and growth rate of Cymbalta 2013-2015 ($ billions)
      • Table Eli Lilly: YoY revenue and growth rate of Evista 2013-2015 ($ billions)
      • Table Eli Lilly: Geographical segmentation of Evista 2015
      • Table Eli Lilly: YoY revenue and growth rate of Forteo 2013-2015 ($ billions)
      • Table Eli Lilly: Geographical segmentation of Forteo 2015
      • Table Eli Lilly: Metrics analysis
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report